Genialis, a computational bioinformatics company, has raised more than USD 13 million in a Series A funding round led by Taiwania Capital and Debiopharm Innovation Fund, with participation from P5 Health Ventures and existing investors. This brings total funds raised to USD 15.5 million.
The funds will be used to expand the company’s ResponderID platform, develop next-generation patient classifiers using machine learning and high-throughput omics data, and build out clinically validated biomarker models to provide pinpoint diagnoses for cancer patients. The funds will also be used to grow its teams in the US and Slovenia.
Genialis is a computational precision medicine company that uses its machine-learning-driven ResponderID platform to provide biomarkers for disease modeling, drug development, and clinical care. The company has collaborated with biopharma to analyze clinical trial data and inform future trial designs for investigational drugs, and supports the commercialization of next-gen biomarker assays with leading diagnostic firms.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.